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SUMMARY
COVID-19 is the disease caused by the novel coronavirus,
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), which first arose in Wuhan, China, in December
2019 and has since been declared a pandemic. The
clinical sequelae vary from mild, self-limiting upper
respiratory infection symptoms to severe respiratory
distress, acute cardiopulmonary arrest and death.
Otolaryngologists around the globe have reported a
significant number of mild or otherwise asymptomatic
patients with COVID-19 presenting with olfactory
dysfunction. We present a case of COVID-19 resulting in
intensive care unit (ICU) admission, presenting with the
initial symptom of disrupted taste and flavour perception
prior to respiratory involvement. After 4 days in the ICU
and 6 days on the general medicine floor, our patient
regained a majority of her sense of smell and was
discharged with only lingering dysgeusia. In this paper,
we review existing literature and the clinical course of
SARS-CoV-2 in relation to the reported symptoms of
hyposmia, hypogeusia and dysgeusia.

Background
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For many sick people with viral upper respiratory
infections (URIs), the experience of eating food and
perceiving flavour is often blunted either secondarily from rhinitis and resulting nasal obstruction
or from direct viral injury to olfactory neuroepithelium. Retronasal olfaction, a combination of
orthonasal smell and taste, is a sensory process that
allows humans to perceive flavour, which is defined
as the perception of anything beyond the five
taste dimensions of food: sweet, salty, bitter, sour
and umami.1 This process is temporarily impaired
during URIs due to mucosal inflammation and
congestion of the nasal passages, thus physically
blocking the entry of odour and flavour molecules
to the olfactory cleft.2 In contrast, post-URI olfactory loss is a neural process that occurs due to viral
insult2 and most commonly results in hyposmia late
in the course of viral infection.3 This type of viral
insult can result in either temporary loss of olfaction or, in some cases, permanent loss of smell.
Severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) is one of many pandemic coronaviruses that have been identified. The current
outbreak of COVID-19 that began in Wuhan, China,
has constituted a public health emergency of international concern, now creating a global impact with
over 2.4 million cases to date.4 The clinical sequelae
vary from mild and self-limiting URI symptoms to

severe respiratory distress, acute cardiopulmonary
arrest and death.5 Coronaviruses have previously
been identified as a family of viruses associated with
anosmia.6 Anecdotal evidence from otolaryngologists worldwide has suggested that otherwise mild
cases of COVID-19 caused by the novel betacoronavirus, SARS-CoV-2, may be significantly associated with olfactory dysfunction.
We present a case of COVID-19 resulting in ICU
admission, presenting with the initial symptom
of disrupted taste and flavour perception prior to
respiratory involvement. The purpose of this paper
was to review the clinical course of SARS-CoV-2 in
relation to the reported symptom of hyposmia and
hypogeusia.

Case presentation
A 59-year-old African–American female presented
to our institution by ambulance on 29 March 2020,
secondary to several days of shortness of breath,
fatigue and loss of appetite. Medical history was
significant for hypertension, hyperlipidaemia
and asthma, requiring infrequent use of albuterol
reported less than one time per month. Social
history was notable only for a remote history of
tobacco abuse, but she denied any current tobacco,
drug or alcohol use. Of note, the patient did
endorse that her husband, whom she lives with at
home, was complaining of shortness of breath and
a non-productive cough several days prior to her
arrival. Her husband’s symptoms lasted only 3–4
days and had resolved completely. She reported no
past otolaryngological surgeries or use of any nasal
sprays, or homeopathic or herbal medications.
Roughly a week prior to admission, the patient
began to experience a subtle decrease in appetite
and disinterest in food. These symptoms were
isolated and preceded any indication that she was ill.
Over the week prior to her presentation, the foods
she normally enjoys tasted ‘bland and metallic’. The
patient described her diet as ‘varied and including
many spices and strong flavours, particularly using
herbs in Jamaican and Caribbean cuisines’. When
questioned further, she also admitted to a slowly
diminishing ability to smell that progressed to
complete anosmia in the absence of congestion or
any other nasal symptoms. However, she did not
make the connection to this early symptom and
the subsequent respiratory distress until specifically questioned. She noted in particular that when
preparing her normal meals, she could no longer
appreciate any of the typical culinary aromas.
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Figure 1 Chest radiograph, AP, day of admission. AP, anterior–
posterior; R, right.
Further, she could not smell any of her scented candles but did
not think anything of it at that time. The patient denied any
history of hyposmia or anosmia prior to this. It was not until
a few days later when she developed a non-productive cough,
malaise, shortness of breath and chest tightness that ultimately
prompted her to call 911. On transit to the hospital via ambulance, the patient had an initial SpO2 of 68% on room air, and
she was later placed on supplemental oxygen.
Review of symptoms was negative for any nasal obstruction,
rhinorrhea, epistaxis, and nasal or head trauma. She endorsed
shortness of breath, malaise and chest tightness as mentioned
previously. On admission, the patient was afebrile and saturating
adequately on 5 L supplemental oxygen via nasal cannula. The
patient appeared fatigued and mildly distressed, and physical
exam was notable for bilateral wheezes and rales, most predominant at the lung bases bilaterally. The patient had no appreciated
mucosal or turbinate hypertrophy in the nasal cavity and otherwise had a normal head, eyes, ears, nose and throat examination.

Investigations

Laboratory values were significant for lactate dehydrogenase
(410), erythrocyte sedimentation rate (42) and C reactive protein
(192.1). Basic metabolic panel, liver function, renal function,
myocardial enzymes and serum procalcitonin were otherwise
normal. Tests for influenza A/B and Legionella were negative.
A SARS-
CoV-2 nucleic acid amplification test (NAAT) was
taken by nasopharyngeal swab. A chest radiograph (see figure 1)
followed by a high-resolution CT of the chest were performed,
images of which reported multiple patchy ground-glass opacities
in bilateral subpleural areas (see figure 2).

Treatment

Based on the overall clinical picture, the patient remained on
contact and droplet precautions and isolation as it was assumed
that she did have COVID-19. On the consult of our infectious
2

disease physician and checking the patient’s corrected QT interval
(QTc), the patient was empirically treated with the experimental
therapy of hydroxychloroquine 400 mg two times per day for
1 day followed by 200 mg two times per day for 4 days, as well
as azithromycin 500 mg two times per day for 1 day followed by
250 mg two times per day for 4 days.
The patient was subsequently transferred from the general
floor to the ICU on the night of admission due to increased
oxygen requirements with significant desaturations. The patient
was initially placed on a non-
rebreather and transitioned to
continuous positive airway pressure (CPAP). On the advice of
our pulmonologist, she remained on CPAP and intravenous
steroids were initiated. The decision of early and pre-emptive
intubation was discussed with our staff, but the patient did not
display significant and continual signs of respiratory distress to
necessitate this. While the patient was in the ICU, the result of
the SARS-CoV-2 NAAT was positive for detection of the virus
on 2 April 2020.

Outcome and follow-up

The patient remained in the ICU for 4 days and was subsequently
downgraded to the general floor when it was felt that her respiratory status was improving, as she no longer required CPAP.
On discharge on 8 April 2020, 10 days following admission, the
patient endorsed that she had regained a majority of her sense of
smell and that her sense of taste was greatly improved, although
she did state foods did taste ‘excessively salty’ but no longer tasted
metallic as noted before. She was not retested for SARS-CoV-2
prior to discharge but was advised to self-quarantine for 14 days
on returning home. To limit exposure to the patient’s primary
care physician, the patient was instructed to call her physician as
an outpatient to review her hospitalisation. She was instructed
to return to the emergency room only if she experienced severe
symptoms of respiratory distress or other alarming symptoms. A
timeline detailing our patient’s clinical course in relation to her
gustatory and olfactory complaints is shown in figure 3.

Discussion

SARS-CoV-2, a betacoronavirus, is an enveloped positive sense
RNA virus7 that first arose in Wuhan, China, in December 2019.
Officially declared a pandemic on 11 March by the WHO,8
COVID-19, caused by the novel coronavirus SARS-CoV-2, has
affected over 2.4 million patients globally and resulted in over
169 000 deaths as of 20 April 2020.4
Throughout recent weeks, reports of anosmia as a symptom of
COVID-19 have flooded the media. Otolaryngologists around
the globe have reported a significant number of patients with
COVID-19 presenting with olfactory dysfunction,9 but scientific data have proven that a significant association has been
Melley LE, et al. BMJ Case Rep 2020;13:e236080. doi:10.1136/bcr-2020-236080
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Figure 2 Chest CT, axial (A) and coronal (B), day of admission.
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limited. A recent study in Italy using a patient questionnaire
found that approximately one-third (20 of 59) of patients hospitalised with COVID-19 reported some degree of olfactory or
gustatory dysfunction.10 Another recently accepted publication also involving olfactory and gustatory questionnaires was
conducted at 12 European hospitals.11 Among the 417 mild-
to-
moderate European patients with COVID-19 involved in
the Lechien et al study, 85.6% and 88.0% reported olfactory
and gustatory dysfunction, respectively. The majority (65.7%)
of patients reported olfactory dysfunction occurring after the
appearance of general ears, nose and throat symptoms; however,
11.8% of patients in this study reported olfactory dysfunction
appearing before any other symptoms, suggesting anosmia
may be important for early COVID-19 detection. They did not
assess the prevalence of gustatory dysfunctions appearing as the
first symptom, similar to how our patient presented. Additionally, olfactory dysfunction was not significantly associated with
rhinorrhea or nasal obstruction,11 hinting that the mechanism by
which SARS-CoV-2 causes anosmia may be distinguishable from
that of other common URI-causing viruses. However, Lechien et
al did find significant associations between olfactory outcomes
and several variables, including a significant association between
fever and anosmia (p = 0.014). Furthermore, women were
proportionally more affected by hyposmia or anosmia compared
with men (p < 0.001).11 While more data are needed to determine
if gender is a predisposing factor to the development of anosmia,
the predilection for women in this study may be explained by sex
dimorphisms in the olfactory bulb itself. A past study involving
postmortem brains conducted in Brazil found that women have
more neurons in the olfactory bulb.12 The higher susceptibility of women to develop olfactory and subsequent gustatory
dysfunction may also be related to sex differences in inflammatory cytokine production.13 Future studies exploring gender and
additional demographic differences in patients with COVID-19
who experience anosmia are warranted.
The study of anosmia in COVID-19 has not been limited
to Europe. Using a questionnaire sent out to over 10 000 residents in all provinces of Iran, a study that is now in preprint
found that there is a significant correlation between anosmia
and COVID-19 in the different provinces.14 However, reports
of anosmia in Asia have not been robust. To our knowledge,
Mao et al’s study, which details the neurological manifestations
of 214 patients hospitalised with COVID-19 in Wuhan, China,
Melley LE, et al. BMJ Case Rep 2020;13:e236080. doi:10.1136/bcr-2020-236080

is one of the only studies that mention olfactory and gustatory dysfunction as symptoms associated with SARS-CoV-2.15
In contrast to the European studies, only 5.1% and 5.6% of
patients in Mao et al’s study reported hyposmia and hypogeusia,
respectively.15 Earlier studies originating from the virus’ original
epicentre of Wuhan have failed to mention effects on olfactory
and gustatory sensation at all.16 17 This evokes many questions
regarding the significance of anosmia and why it seems to be
so prevalent in European populations yet hardly addressed in
Asian papers. One explanation may be explained by variation
in the SARS-CoV-2 genome. Analyses have revealed two major
types of SARS-CoV-2, S and L, which are defined by their single-
nucleotide polymorphisms.18 The L type was more prevalent
in early stages of the outbreak in Wuhan, but its frequency has
decreased.18 Emerging studies have also demonstrated continued
evolution of SARS-
CoV-2 in regard to its surface proteins,
particularly the spike glycoprotein.19 20 This glycoprotein is
necessary for binding cell receptors and thus determines host
tropism,19 20 which may explain the potential clinical differences
between patients of distinct demographic areas. Another possibility is that patients with COVID-19 in the Asian population in
fact did have anosmia with associated hypoguesia and dysguesia,
yet these symptoms went un-noticed or under-reported. Unlike
the loss of sight, which is readily apparent to others, anosmia can
be particularly insidious and go unnoticed. As in the case of our
patient, she did not realise she had anosmia until her perception
of flavour and ability to enjoy foods were affected. For patients
who eat primarily bland foods, such as white rice, which is a
staple of the Chinese diet, anosmia and its subsequent impairment on retronasal olfaction may not be evident. The need for
further scientific study involving validated smell tests to determine the significance is apparent. The implications of hyposmia
and the overall use of olfactory performance measures to either
support or diagnose the prognosis in COVID-19 go beyond the
acute disease state itself. It is well known in the literature that
individuals with persistent olfactory dysfunction are at particular risk for nutritional deficiencies, development of depression and other psychiatric disorders, and the inability to detect
certain ‘warning/danger’ odours like natural gas, smoke, spoiled
foods and other noxious gases.21 On 22 March 2020, a statement released from the American Academy of Otolaryngology–
Head and Neck Surgery (AAO-HNS), ‘Anosmia, hyposmia, and
dysgeusia in the absence of other respiratory disease such as
3
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Figure 3 Timeline of our patient’s clinical course with COVID-19. CPAP, continuous positive airway pressure; ICU, intensive care unit; NAAT, nucleic
acid amplification test.
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Contributors LEM contributed to project conception, writing/manuscript
preparation: writing the majority of the initial draft as well as contributing to draft
4

Patient’s perspective
This section highlights the patient’s direct quotes regarding the
initial presentation of her disease, the progression that led her to
the ICU and her eventual improvement and discharge from the
hospital.
►► ‘My husband was initially sick with what we thought was a
cold. We were keeping up with the COVID-19 news and did
not think that his symptoms could be it, because other than
going to the grocery store, we had no direct contact with
anyone. I then started to get really winded and began to
cough. It was not until I spoke to the doctor at the hospital
when I realized that my sense of taste and smell were off.
Everything I was eating tasted off although they were recipes
I made frequently. I did not know that my loss of smell was
related to COVID’.
►► ‘When the doctors told me I may have COVID I was very
nervous and feared for my life. Everything that I heard on the
news made me even more concerned about this. I had also
wondered if my husband did in fact have COVID in the first
place but got over it’.
►► ‘I am thankful to have noticed early on to come to the
hospital when I started having issues breathing as I believe
my outcome would be a lot worse hadn’t I called 911’.

Learning points
►► Anosmia, dysgeusia and hypogeusia appear to be early

presenting symptoms of COVID-19 in select patients that may
occur prior to respiratory symptoms.
►► While only recently added to the Centers for Disease Control
and Prevention’s list of symptoms and not yet considered
stand-alone symptoms that warrant COVID-19 testing, new-
onset anosmia, hypogeusia and/or dysgeusia (especially in
the absence of nasal congestion) should prompt strict self-
isolation to limit presumptive viral spread.
►► For many, the experience of smell and its lack thereof can
be particularly insidious and go relatively unnoticed without
large disruption in day-to-day life.
►► As clinicians, we need to be keen on these subtle and
overlooked symptoms of COVID-19, especially when objective
tests for anosmia are not readily available to most providers.
►► Although purely anecdotal evidence for the relationship
between COVID-19 infection and the symptoms of hyposmia
and hypogeusia, these remain concerning symptoms and
prompt further investigation.
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allergic rhinitis, acute rhinosinusitis, or chronic rhinosinusitis
should alert physicians to the possibility of COVID-19 infection
and warrant serious consideration for self-isolation and testing
of these individuals’. On 26 March, the AAO-HNS released an
anosmia reporting tool to assess for the significance of these
symptoms in the diagnosis and progression of COVID-19.22 In a
study analysing the first 237 of the tool’s entries, Kaye et al found
that anosmia was present in 73% of subjects prior to COVID-19
diagnosis and was the initial symptom in 26.6%. The most
common symptoms to present before anosmia included cough
(41%), malaise (39%), fever (38%) and headache (37%). Gastrointestinal (GI) distress was the least likely symptom to present
before anosmia, occurring in 10% of patients.23 Similar to olfactory dysfunction, patients with COVID-19 presenting with GI
symptoms have garnered particular media attention and have
been subject to a recent study. In a study conducted among three
hospitals in China, 18.6% of patients with COVID-19 presented
with a GI-specific symptom, including diarrhoea, vomiting or
abdominal pain. They also found that patients with COVID-19
may present with digestive symptoms, even in the absence of
respiratory symptoms, although this occurred only in <1% of
patients.24 Similarly, in a study conducted in the USA involving
116 patients with confirmed SARS-CoV-2 infection, 31.9% of
patients reported GI symptoms. This included loss of appetite
(22.3%), nausea/vomiting (12.0%) and diarrhoea (12.0%) as the
most common GI symptoms. None of the patients in this study
developed isolated GI symptoms or GI symptoms as an initial
manifestation of SARS-CoV-2 infection.25 Although more data
are needed, it seems that anosmia and hypogeusia may be more
likely as initial symptoms in COVID-19.
Additional studies using objective olfactory and gustatory tests
are necessary to establish the significance of anosmia and hypogeusia in patients with COVID-19. Nonetheless, preliminary
research suggests that gustatory or olfactory complaints during a
viral pandemic should not be ignored. In a study based in the USA
using a survey sent out to both patients positive for COVID-19
and patients negative for COVID-19 with influenza-like symptoms, smell and taste loss were reported in 68% (40/59) and
71% (42/59) of subjects positive for COVID‐19, respectively,
compared with 16% (33/203) and 17% (35/203) of patients
negative for COVID‐19 (p<0.001). Their results showed these
chemosensory impairments were at least 10-fold more common
in COVID-19-
positive cases than COVID-19-
negative cases,
both presenting with similar influenza-like symptoms.26 While
the authors of this study did not reveal how many of these
patients tested positive for influenza virus,26 past studies have
demonstrated that influenza is not significantly associated with
change in smell.27 Furthermore, postviral olfactory disorders due
to other common viruses has an estimated prevalence of around
11%–40%,28 which appears much less common than that seen
with SARS-CoV-2 infection according to existing studies. Future
research should also investigate the frequency of olfactory and
gustatory dysfunctions in patients infected with influenza and
other common viruses, in order to confirm the significance of its
correlation with COVID-19.
Our unique patient case and the aforementioned literature
highlight the importance of the physicians’ ability to identify these subtle and sometimes unnoticed symptoms of this
pandemic-
creating virus. Peer-
reviewed scientific literature
is needed to further elucidate this early finding and to better
understand the overall clinical course of SARS-CoV-2.
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